tiprankstipranks
Trending News
More News >

Psyence Biomedical Advances Psilocybin Trial with New CRO Agreement

Story Highlights
Psyence Biomedical Advances Psilocybin Trial with New CRO Agreement

Don’t Miss TipRanks’ Half-Year Sale

Psyence Biomedical ( (PBM) ) has provided an update.

Psyence Biomedical Ltd. announced that its subsidiary, Psyence Australia Pty Ltd, has entered into a Master Services Agreement with Southern Star Research Pty Ltd to conduct a Phase IIb clinical trial for its psilocybin drug candidate, PEX010. This agreement, finalized on May 21, 2025, marks a significant step in evaluating PEX010 for treating adjustment disorder in cancer patients. Southern Star Research will provide comprehensive contract research services, including trial management, data management, regulatory support, and patient recruitment. This collaboration is expected to enhance Psyence’s operational capabilities and strengthen its position in the psychedelic therapy market.

More about Psyence Biomedical

Psyence Biomedical Ltd. operates in the biotechnology industry, focusing on psychedelic-assisted therapy. The company is involved in developing psilocybin-based treatments, particularly targeting adjustment disorders in cancer patients.

Average Trading Volume: 85,491

Technical Sentiment Signal: Sell

Current Market Cap: $3.04M

For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1